George Frangeskides, Chairman at ALBA, explains why the Pilbara Lithium option ‘was too good to miss’. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
I call this a total scam. It will take years for this share to recover.
Pokerchips - the fully diluted nosh puts the market cap way higher than company has been suggesting. It is their usual unprofessional approach to investor relations, which has done them no favours over the years. Where the additional 285m shares comes from is a puzzle the company is not too interested in clarifying - for obvious reasons - though they used to publish a total share capital, that has now stopped. “ Fo llowing Admission, the Company's issued share capital will comprise 325,803,104 Ordinary Shares with one voting right each and 284,984,933 deferred shares with no rights to vote.”… still looks decent value even with 610m shares in issue, and as you suggest they would receive cash from some of the issuance, but a large reason for the “decent value” is that no one trusts the story presented. How NOT to do investor relations.
Lambo222,
As usual , you ramp like hell when it suits you …
My contrarian question is why did Avion allow this monstrous dilution to shareholders ( with the warrants to L1 and Lind ) ?
If IMM had any consideration for their shareholders, there is no way that they would have done this last placing under 11p ( which opened the door for the warrants at 5p )
This is what I call ´highlight robbery ‘ and will affect the SP for many years to come ( whatever the Newsflow ) imo
L1 and Lind now have 56,408,558 Options with an exercise price of 5p exercisable up to 10 June 2023, which would bring in £2.8m if indeed fully exercised, but would bring a 17% dilution
All hinges on outcome 29th Avion willing to spend a lot of money on successful outcome im confident if they are. Only time will tell
Agreed, though IMM is really only funded for the next 12 months assuming the FDA allows Phase 3 to proceed. Otherwise it's basically all over. I know Tim'n'Tim's recent presentation stressed all the other potential revenue streams. But these were much further into the future (assuming any succeeded). If the FDA's final guidance unexpectedly threw a spanner in the works, IMM would have an IMMense funding problem. So let's hope the BOD's confidence is finally justified this time, as we've been led down the garden path before. And the resulting share price wasn't pretty.
Anyway good to see we are now funded for the next 12 months, directors took 10% of the placing which is a positive and are willing to defer wages, now come on FDA let’s get this show in the road…
It was 2018… and around £250m Mcap, Lupozor has long been touted as a blockbuster billion pound drug, Avion obviously think the same as their CEO commented that he envisioned Lupozor becoming the lead drug in their portfolio… the potential is huge, it just needs to deliver, if the bod and the drug delivers then we will see £250m Mcap again no problem which is a near 20 bagger from these levels! I hve around £25k invested and will just leave it to hold for gold as in a few years time there is the chance that £25k could be worth £500k if all goes to plan it’s a risk I’m willing to take as the potential rewards on offer are life changing
How did this ever reach about £1.80 on no revenue about 2016 just asking
Dallo ,
I agree with a lot of what you are saying but one has to be reasonable when it comes to IMM especially after this last fund raising with all the warrants etc etc . Dilution is the main problem here for quite some time and it’s the main reason why IMM has a market cap of 16-20 million for the last 2 years , imo
Then you have to factor in the Tim element :-)
Nolupus
Yes but if the FDA approves the Phase 3 we are in a different investment situation and the speculative pot will boil right up to the results.
The starting gun will be set a base for the SP and it should be a lot higher than 5.5p imho.
Investors can choose to get out in a month/ 6 months et al or top slice as we get nearer the results.
Our options will be a lot better if the Phase 3 is approved...conversely we will have no options if it is turned down imho
Sounds like a SCP employee talk to me :-)
Whatever
True but from £16m Mcap if it did actually manage to get $150m in royalties per year from the US market alone with only Lupus, the scope for life change potential is there, if this company could generate $150m a year profit some time in the future you are looking at a £billion company which from current levels would be a 100 bagger…. Pie in the sky figures I know but if all went to plan that’s where IMM could get to and there are not many companies on aim if any who have this potential
Lambo222,
The go ahead from the FDA is just the starting gun .. the P3 trial will take time and the result is not guaranteed.
A reasonable punt Ok but ….
Some big volume coming in last hour or so, mainly all buys, the broker option closes today so we should get an rns tomorrow, be interesting to see if it was filled, would personally rather it wasn’t fully subscribed so there’s no overhang, directors took £100k of it which is positive so only £1.2m up for grabs, little over 2 weeks to go before we find out if this company is going to make us life changing returns or big losses, what’s certain is if Tim is right when he said in the presentation that we can get $100-$150m in royalties each year from Lupozor in US sales alone, then my god a lot of millionaires are going to be made buying at this level, the FDA decision unlocks so much here after been in the doldrums for so many years, maybe just maybe it’s about to rise from the ashes
My buy been labelled as as sell ? Any reason?
Some on here have huge holdings and dwarf mine. In throwing out old copies of Shares Mag recently, I came across December 2017 edition which says "Drug developer ImmuPharma is expecting phase III results in first quarter of 2018 for lupus treatment Lupuzor. Analysts speculate the drug could hit multi billion dollar annual sales if the tests are successful and the drug gets approved by the regulators.
So this is a good time to buy but the risk reward remains high especially the reward side.
Hi Dallo! We have almost the same holding here so I wish you the best of luck! It is about time for the board to deliver and get great results.
Oscar
Best of luck...I have 2.5 million shares at 16p and have been here for a million years or so it seems like.
We will know a lot more in a couple of weeks.
10 Aug 2022 Buy IMM 310,000 5.222p £16,199.70 *Executed *
* P-1027** * IMMUPHARMA PLC *
Another top-up. Good luck and enjoy the ride!
In past i would have been bit sceptical but with Avion consulting all the way along with FDA i feel they havent taken any chances and following all FDA requirements.
10 Aug 2022 Buy IMM 165,000 5.213p £8,611.95 *Executed *
* P-1027** * IMMUPHARMA PLC *
Good luck to long-term shareholders!
Money to be made here.
No bid currently; yet this will change shortly.
I am buying.
The valuation is low because the market doesn't understand the science. It will make sense to the market as phase 3 begins and IMM release more news. The deligent investors will be rewarded.
oscar22 - resorting to rudeness. A classic sign you’ve lost the argument. Never mind.